These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 34342437

  • 21. Hypoxia Active Platinum(IV) Prodrugs of Orotic Acid Selective to Liver Cancer Cells.
    Maji M, Bhattacharya I, Acharya S, Chakraborty MP, Gupta A, Mukherjee A.
    Inorg Chem; 2021 Apr 05; 60(7):4342-4346. PubMed ID: 33711231
    [Abstract] [Full Text] [Related]

  • 22. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
    Reshetnikov V, Arkhypov A, Julakanti PR, Mokhir A.
    Dalton Trans; 2018 May 15; 47(19):6679-6682. PubMed ID: 29708261
    [Abstract] [Full Text] [Related]

  • 23. Enhanced Cytotoxicity and Reactivity of a Novel Platinum(IV) Family with DNA-Targeting Naphthalimide Ligands.
    Navas F, Mendes F, Santos I, Navarro-Ranninger C, Cabrera S, Quiroga AG.
    Inorg Chem; 2017 Jun 05; 56(11):6175-6183. PubMed ID: 28488859
    [Abstract] [Full Text] [Related]

  • 24. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
    Qin X, Fang L, Zhao J, Gou S.
    Inorg Chem; 2018 May 07; 57(9):5019-5029. PubMed ID: 29667815
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines.
    Petruzzella E, Braude JP, Aldrich-Wright JR, Gandin V, Gibson D.
    Angew Chem Int Ed Engl; 2017 Sep 11; 56(38):11539-11544. PubMed ID: 28759160
    [Abstract] [Full Text] [Related]

  • 30. A Dual Killing Strategy: Photocatalytic Generation of Singlet Oxygen with Concomitant PtIV Prodrug Activation.
    Norman DJ, Gambardella A, Mount AR, Murray AF, Bradley M.
    Angew Chem Int Ed Engl; 2019 Oct 01; 58(40):14189-14192. PubMed ID: 31397963
    [Abstract] [Full Text] [Related]

  • 31. Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs.
    Shi H, Romero-Canelón I, Hreusova M, Novakova O, Venkatesh V, Habtemariam A, Clarkson GJ, Song JI, Brabec V, Sadler PJ.
    Inorg Chem; 2018 Nov 19; 57(22):14409-14420. PubMed ID: 30365308
    [Abstract] [Full Text] [Related]

  • 32. Multifunctional Pt(iv) prodrug candidates featuring the carboplatin core and deferoxamine.
    Harringer S, Hejl M, Enyedy ÉA, Jakupec MA, Galanski MS, Keppler BK, Dyson PJ, Varbanov HP.
    Dalton Trans; 2021 Jun 21; 50(23):8167-8178. PubMed ID: 34031671
    [Abstract] [Full Text] [Related]

  • 33. Novel hypoxia-targeting Pt(iv) prodrugs.
    Xu Z, Zhao J, Gou S, Xu G.
    Chem Commun (Camb); 2017 Mar 28; 53(26):3749-3752. PubMed ID: 28303266
    [Abstract] [Full Text] [Related]

  • 34. Fluorogenic platinum(IV) complexes as potential predictors for the design of hypoxia-activated platinum(IV) prodrugs.
    Marsh JW, Hacker L, Huang S, Boulet MHC, White JRG, Martin LAW, Yeomans MA, Han HH, Diez-Perez I, Musgrave RA, Hammond EM, Sedgwick AC.
    Dalton Trans; 2024 Sep 10; 53(35):14811-14816. PubMed ID: 39169877
    [Abstract] [Full Text] [Related]

  • 35. Strong in vitro and vivo cytotoxicity of novel organoplatinum(II) complexes with quinoline-coumarin derivatives.
    Qin QP, Wang ZF, Huang XL, Tan MX, Zou BQ, Liang H.
    Eur J Med Chem; 2019 Dec 15; 184():111751. PubMed ID: 31593828
    [Abstract] [Full Text] [Related]

  • 36. Optimization of axial ligands to promote the photoactivation of BODIPY-conjugated platinum(IV) anticancer prodrugs.
    Yao H, Gunawan YF, Liu G, Tse MK, Zhu G.
    Dalton Trans; 2021 Oct 12; 50(39):13737-13747. PubMed ID: 34519297
    [Abstract] [Full Text] [Related]

  • 37. Vitamin B₁₂ as a carrier for targeted platinum delivery: in vitro cytotoxicity and mechanistic studies.
    Ruiz-Sánchez P, König C, Ferrari S, Alberto R.
    J Biol Inorg Chem; 2011 Jan 12; 16(1):33-44. PubMed ID: 20803225
    [Abstract] [Full Text] [Related]

  • 38. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
    Liu Z, Wang M, Wang H, Fang L, Gou S.
    Eur J Med Chem; 2020 May 15; 194():112269. PubMed ID: 32248002
    [Abstract] [Full Text] [Related]

  • 39. Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.
    Pichler V, Mayr J, Heffeter P, Dömötör O, Enyedy ÉA, Hermann G, Groza D, Köllensperger G, Galanksi M, Berger W, Keppler BK, Kowol CR.
    Chem Commun (Camb); 2013 Mar 18; 49(22):2249-2251. PubMed ID: 23396381
    [Abstract] [Full Text] [Related]

  • 40. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance.
    Ma J, Li L, Yue K, Li Y, Liu H, Wang PG, Wang C, Wang J, Luo W, Xie S.
    Bioorg Chem; 2020 Jun 18; 99():103768. PubMed ID: 32217375
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.